Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.31 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949439 | 0.88 | — | — | |
| SCHEMBL4229152 | 0.85 | PIM1 (0.32) | PIM1PIM2KDM1ARCOR1GPR174 | |
| SCHEMBL4597955 | 0.78 | DDB1 (0.40) | — | |
| SCHEMBL4519196 | 0.70 | DDB1 (0.37) | — | |
| SCHEMBL4229295 | 0.62 | PIM1 (0.38) | PIM1PIM2 | |
| SCHEMBL949438 | 0.58 | SLC6A4 (0.40) | PIM1PIM2KDM1ARCOR1GPR174 | |
| SCHEMBL31579405 | 0.57 | KDM1A (0.40) | PIM1PIM2KDM1ARCOR1GPR174 | |
| SCHEMBL31579709 | 0.57 | MMP2 (0.48) | PIM1PIM2KDM1ARCOR1GPR174 | |
| SCHEMBL4564168 | 0.55 | L3MBTL1 (0.47) | KDM1ARCOR1L3MBTL1 | |
| SCHEMBL254957 | 0.55 | MAPT (0.56) | PIM1PIM2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029700-A1 | 1-(2-ARYL-2-OXOETHYL)-3-PHENYL-1, 4-DIAZASPIRO [4.5]DEC-3-EN-2-ONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029700-A1 | 1-(2-ARYL-2-OXOETHYL)-3-PHENYL-1, 4-DIAZASPIRO [4.5]DEC-3-EN-2-ONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS | SLC1A1, SLC1A5, SLC6A5 | PIM1 3819/4885PIM2 3916/4885KDM1A 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.